nach oben

Diabetologia

Erschienen in:

01.10.2006 | Article

Insulin-like growth factor I: a predictor of long-term glucose abnormalities in patients with acute myocardial infarction

verfasst von: M. Wallander, K. Brismar, J. Öhrvik, L. Rydén, A. Norhammar

Erschienen in: Diabetologia | Ausgabe 10/2006

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Low levels of IGF-I are associated with increased risk of cardiovascular disease and type 2 diabetes. The aim of this study was to investigate the IGF-I system in patients with acute myocardial infarction (AMI) without previously known diabetes.

Materials and methods

One hundred and sixty-eight AMI patients were classified before hospital discharge by means of an OGTT as having NGT, IGT or newly detected type 2 diabetes. Age- and sex-matched subjects from the background population (n=185) served as the control group. The associations between fasting levels of IGF-I and IGF binding proteins 1 and 3 (IGFBP-1, IGFBP-3) and glucose metabolism during a follow-up period of 12 months were studied.

Results

At hospital discharge, age-adjusted IGF-I (IGF-I SD) was significantly lower in patients with abnormal glucose tolerance (AGT=IGT or type 2 diabetes) compared with patients with NGT (p=0.014) and control subjects (p<0.001). IGF-I was strongly correlated with IGFBP-3 (r=0.730, p<0.001), which was significantly lower in patients with AGT compared with patients with NGT (p=0.009) and control subjects (p<0.001). Fasting levels of IGFBP-1 did not differ significantly between patients with NGT and AGT or between patients and control subjects. In a multiple logistic regression analysis in patients, IGF-I at hospital discharge was a significant predictor of AGT at discharge and after 12 months (adjusted odds ratio 0.29, p=0.022, and adjusted odds ratio 0.29, p=0.034, respectively).

Conclusions/interpretation

Low levels of IGF-I may be a useful predictor of abnormal glucose metabolism in patients with AMI.

Coutinho M, Gerstein HC, Wang Y, Yusuf S (1999) The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22:233–240PubMedCrossRef

Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Ryden L (2004) Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 25:1990–1997PubMedCrossRef

Norhammar A, Tenerz A, Nilsson G et al (2002) Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359:2140–2144PubMedCrossRef

Bartnik M, Ryden L, Ferrari R et al (2004) The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 25:1880–1890PubMedCrossRef

Lewitt MS (1994) Role of the insulin-like growth factors in the endocrine control of glucose homeostasis. Diabetes Res Clin Pract 23:3–15PubMedCrossRef

Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ (2002) Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 359:1740–1745PubMedCrossRef

Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D (2004) The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 89:114–120PubMedCrossRef

Spallarossa P, Brunelli C, Minuto F et al (1996) Insulin-like growth factor-I and angiographically documented coronary artery disease. Am J Cardiol 77:200–202PubMedCrossRef

Heald AH, Siddals KW, Fraser W et al (2002) Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes. Diabetes 51:2629–2636PubMedCrossRef

10.

Schuler-Luttmann S, Monnig G, Enbergs A et al (2000) Insulin-like growth factor-binding protein-3 is associated with the presence and extent of coronary arteriosclerosis. Arterioscler Thromb Vasc Biol 20:E10–E15PubMed

11.

Ruotolo G, Bavenholm P, Brismar K et al (2000) Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. J Am Coll Cardiol 35:647–654PubMedCrossRef

12.

Harrela M, Qiao Q, Koistinen R et al (2002) High serum insulin-like growth factor binding protein-1 is associated with increased cardiovascular mortality in elderly men. Horm Metab Res 34:144–149PubMedCrossRef

13.

Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T (2002) Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 106:939–944PubMedCrossRef

14.

Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3–34PubMedCrossRef

15.

Lewitt MS, Denyer GS, Cooney GJ, Baxter RC (1991) Insulin-like growth factor-binding protein-1 modulates blood glucose levels. Endocrinology 129:2254–2256PubMedCrossRef

16.

Bartnik M, Malmberg K, Hamsten A et al (2004) Abnormal glucose tolerance—a common risk factor in patients with acute myocardial infarction in comparison with population-based controls. J Intern Med 256:288–297PubMedCrossRef

17.

Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef

18.

ESC (2000) Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 21:1502–1513CrossRef

19.

Bang P, Eriksson U, Sara V, Wivall IL, Hall K (1991) Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh) 124:620–629

20.

Povoa G, Roovete A, Hall K (1984) Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol (Copenh) 107:563–570

21.

Hilding A, Brismar K, Degerblad M, Thoren M, Hall K (1995) Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metab 80:2646–2652PubMedCrossRef

22.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef

23.

Öhrvik J (2002) Nonparametric methods in the two-way layout. Chiang Mai J Sci 29:103–115

24.

Wallander M, Bartnik M, Efendic S et al (2005) Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study. Diabetologia 48:2229–2235PubMedCrossRef

25.

Janssen JA, Lamberts SW (2002) The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible? Eur J Endocrinol 146:467–477PubMedCrossRef

26.

DECODE (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397–405CrossRef

27.

Bang P, Brismar K, Rosenfeld RG (1994) Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130- to 150-kDa ternary complex. J Clin Endocrinol Metab 78:1119–1127PubMedCrossRef

28.

Brismar K, Fernqvist-Forbes E, Wahren J, Hall K (1994) Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab 79:872–878PubMedCrossRef

29.

Brismar K, Lewitt MS (2004) The IGF and IGFBP system in insulin resistance and diabetes mellitus. In: Houston MS, Holly JMP, Feldman EL (eds) IGF and nutrition in health and disease. Humana, Totowa, pp 251–270

30.

Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE (2002) Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes 51:2170–2178PubMedCrossRef

31.

Boden G, Shulman GI (2002) Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 32(Suppl 3):14–23PubMedCrossRef

32.

Vaessen N, Heutink P, Janssen JA et al (2001) A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 50:637–642PubMedCrossRef

33.

Leinonen ES, Salonen JT, Salonen RM et al (2002) Reduced IGFBP-1 is associated with thickening of the carotid wall in type 2 diabetes. Diabetes Care 25:1807–1812PubMedCrossRef

Titel: Insulin-like growth factor I: a predictor of long-term glucose abnormalities in patients with acute myocardial infarction
verfasst von: M. Wallander
K. Brismar
J. Öhrvik
L. Rydén
A. Norhammar
Publikationsdatum: 01.10.2006
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 10/2006
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-006-0386-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Insulin-like growth factor I: a predictor of long-term glucose abnormalities in patients with acute myocardial infarction

Abstract

Aims/hypothesis

Materials and methods

Results

Conclusions/interpretation

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Aims/hypothesis

Materials and methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2006

Type 2 diabetes and cardiovascular risk in the UK south Asian community

Genotype-by-sex interaction in the aetiology of type 2 diabetes mellitus: support for sex-specific quantitative trait loci in Hypertension Genetic Epidemiology Network participants

BCL-6: a possible missing link for anti-inflammatory PPAR-δ signalling in pancreatic beta cells

The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells

The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy

Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin